{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fla-art-candidacy-and-counseling-I41f9vxO","width":444,"version":"1.0","type":"rich","title":"Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/a58a4dc2-5af3-4865-ab51-f42471ab35f0/hiv-post-croi-virtual-viiv-sympo-podcasticon-01.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f75e5421-ebe9-4ced-af75-86d06d15fe41\" height=\"200\" width=\"100%\" title=\"Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This podcast episode features an international panel discussion on the nuts and bolts of switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment."}